| Item type |
学術雑誌論文 / Journal Article(1) |
| タイトル |
|
|
タイトル |
Fumarate Hydratase-deficient Renal Cell Carcinoma Successfully Treated with Cabozantinib: A Case Report |
|
言語 |
en |
| 言語 |
|
|
言語 |
eng |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
cabozantinib |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
fumarate hydratase-deficient renal cell carcinoma |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
metastatic renal cancer |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
| アクセス権 |
|
|
アクセス権 |
open access |
|
アクセス権URI |
http://purl.org/coar/access_right/c_abf2 |
| 著者 |
Inoue, Minoru
Izumi, Keita
Ikezoe, Erika
Tsujioka, Hiroki
Hasegawa, Kintaro
Nirazuka, Asumi
Sugie, Miho
Yasuda, Yuka
Osaka, Akiyoshi
Iwahata, Toshiyuki
Nakayama, Akinori
Setoguchi, Kiyoshi
Ide, Hisamitsu
Matsushima, Jun
Ban, Shinichi
Nagashima, Yoji
Saito, Kazutaka
|
| 書誌情報 |
en : Dokkyo Medical Journal
巻 4,
号 2,
p. 134-138,
発行日 2025-04-25
|
| 記事種別 |
|
|
値 |
Case Report |
| 内容記述 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
Fumarate hydratase-deficient renal cell carcinoma arises from mutations in the fumarate hydratase (FH) gene, representing a rare subset of renal cell carcinoma (RCC). Approximately 19% of patients formerly diagnosed with type 2 papillary RCCs are FH deficient. FH-deficient RCC typically exhibits an aggressive course and is associated with hereditary leiomyomatosis and RCC syndrome in cases with germline mutations. Herein, we report the case involving a 34-year-old Japanese man who experienced a 20-kg weight loss. Computed tomography identified a left renal tumor, leading to a subsequent left nephrectomy. Pathological analysis confirmed FH-deficient RCC. Following diagnosis, the patient underwent treatment with ipilimumab and nivolumab for liver metastasis. Due to disease progression, cabozantinib was administered as second-line therapy, achieving a partial response. Currently, no established standard therapy exists for FH-deficient RCC.
Nevertheless, in this case, the multi-kinase inhibitor cabozantinib was effective in combating resistance to immune checkpoint inhibitors. |
|
言語 |
en |
| 出版者 |
|
|
出版者 |
Dokkyo Medical Society |
| ISSN |
|
|
収録物識別子タイプ |
EISSN |
|
収録物識別子 |
2436-522X |
| 書誌レコードID |
|
|
収録物識別子タイプ |
NCID |
|
収録物識別子 |
AA12941861 |
| DOI |
|
|
関連タイプ |
isIdenticalTo |
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
https://doi.org/10.51040/dkmj.2024-006 |
| 出版タイプ |
|
|
出版タイプ |
VoR |
|
出版タイプResource |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
DKMJ-4-2-5.pdf (1 MB)
.png)
